Cutaneous Leishmaniasis Completed Phase 2 Trials for Miltefosine (DB09031)

Also known as: Leishmaniasis, Cutaneous / Cutaneous leishmaniasis (disorder)

IndicationStatusPhase
DBCOND0028439 (Cutaneous Leishmaniasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03445897Miltefosine Plus IL Pentamidine for Bolivian CLTreatment
NCT02687971Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨Treatment
NCT01380314Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous LeishmaniasisTreatment
NCT01050907Miltefosine to Treat Mucocutaneous LeishmaniasisTreatment
NCT00233545Miltefosine to Treat Cutaneous Leishmaniasis in BoliviaTreatment